Alvotech (ALVO)

$3.65 +0.03 (0.83%)
Market Cap 1.10B
Revenue (ttm) 588.90M
Net Income (ttm) 27.92M
EPS (ttm) N/A
PE Ratio 36.20
Forward PE 16.87
Profit Margin 4.74%
Debt to Equity Ratio -6.36
Volume 246,800
Avg Vol 575,738
Day's Range N/A - N/A
Shares Out 301.81M
Stochastic %K 94%
Beta 0.25
Analysts Sell
Price Target $6.80

Company Profile

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosim...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Address:
9, Rue de Bitbourg, Luxembourg, Luxembourg
JohnTill
JohnTill Apr. 4 at 6:49 PM
$ALVO 4.10-4.25 coming within the next 5-7 trading session? Way too obvious? So many things lining up on the chart saying this is the next move (falling wedge, 50MA, etc, etc.). The fundamentals scream double digits within the next 18 months with FDA, US partner and new drug news coming soon so I should not even care but happy with some small baby steps. Now I am pissed I did not more than double up below 3.25 when given the chance but at least now well into the money on the trade. See where the week takes us.
0 · Reply
JohnTill
JohnTill Apr. 1 at 2:39 PM
$ALVO This would be a VERY good time for the company to put out FDA news or annouce a new US partner agreement. Finally some momentum in the right direction at that 50MA at 4.27 is just itching to get tested on news. After that - the GAP! At least I am well into the profit side again with more then tripling my position below 3.25 that in late March. I was definitely not loving buying into the that hole and on to brighter days.
0 · Reply
JohnTill
JohnTill Mar. 31 at 2:38 AM
$ALVO ALVO 20-F released and explains the strength today. I checked the SEC account mid-day and saw nothing but up there now. Well written all public items and could not find anything of major note. The major item is the next 9 months hinges on FDA approval. Approval by October and they will hit the high end of projections and more than enough cash flow for full speed expansion and debt knock-down. I see no reason why they will not get FDA approval and the only question is Sept. or Dec. and two years from now makes little difference. I do like that along with 30+ biosimilars in the pipeline they also talk about acquiring or in-license additional products and expansion into more expensive clinical programs. There are so many bullets in this gun and each one is a billion+ dollar target.
0 · Reply
JohnTill
JohnTill Mar. 30 at 7:49 PM
$ALVO Weird strength in a weak market on no news. Did someone let the cat out of the bag that the FDA filing is coming very soon or the new US partner agreement? Maybe UBS analyst Ashwani Verma buy rating from last week is finally making the rounds. Only a 6.00 price target but that is because everyone is holding out for FDA approval, new US partner and US drug launch. Once those hit we fill the gap and double digits and a rollercoaster until then.
0 · Reply
JohnTill
JohnTill Mar. 26 at 3:57 PM
$ALVO We could use some good news. I just noticed in the conference call notes “So that is why we're in the final stretches of being ready to submit. We're working really hard to do it by the end of the first quarter.”….. FDA news in the next few days? All changes done and running since late 2025. Filing starts the 6 month timer and inventory ready to flood the US potentially as soon as Oct. Also, could get the US partner news anytime and several pipeline updates. Upped my position by 40% this past few days between 3.22 and 3.05. Sitting with mid-3 avg. now and second largest position. Let the sweating starts. Delays get us into the twos and will add more since there is no way this is not healthy double digits by 2028 or sooner.
0 · Reply
Spytime
Spytime Mar. 26 at 1:20 PM
$ALVO waiting to open buy position soon. Waiting for panic retail to sell.
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 24 at 11:42 PM
$ALVO RSI: 31.19, MACD: -0.3075 Vol: 0.28, MA20: 3.77, MA50: 4.47 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
erevnon
erevnon Mar. 24 at 2:44 PM
Barclays maintains Alvotech $ALVO at Underweight and lowers the price target from $5 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
Explorer2234
Explorer2234 Mar. 24 at 2:35 PM
$ALVO lol wtf is going on with the price? Massive upside potential?
0 · Reply
diggs24
diggs24 Mar. 24 at 2:22 PM
$ALVO added 580@$3.07
0 · Reply
Latest News on ALVO
Alvotech files Annual Report with the SEC

Mar 30, 2026, 7:58 PM EDT - 5 days ago

Alvotech files Annual Report with the SEC

Alvotech Publishes 2025 Annual Report

Mar 30, 2026, 7:55 PM EDT - 5 days ago

Alvotech Publishes 2025 Annual Report

Alvotech (ALVO) Q4 2025 Earnings Call Transcript

Mar 19, 2026, 3:12 PM EDT - 16 days ago

Alvotech (ALVO) Q4 2025 Earnings Call Transcript

Alvotech Q4 2025 and Full Year 2025 Financial Results

Mar 18, 2026, 6:15 PM EDT - 17 days ago

Alvotech Q4 2025 and Full Year 2025 Financial Results

Royce Smaller-Companies Growth Fund FY 2025: What Worked

Mar 12, 2026, 8:35 PM EDT - 23 days ago

Royce Smaller-Companies Growth Fund FY 2025: What Worked

ACVA AVAV FROG FRPT HIMS NVO PAR

Alvotech to Report Fourth Quarter and Full Year 2025 Financial Results

Mar 4, 2026, 3:00 AM EST - 4 weeks ago

Alvotech to Report Fourth Quarter and Full Year 2025 Financial Results

Alvotech Announces Increase in Number of Own Shares

Feb 11, 2026, 11:00 AM EST - 7 weeks ago

Alvotech Announces Increase in Number of Own Shares

Alvotech Announces Positive Top-Line Results from Pivotal Pharmacokinetic Study for Proposed Biosimilar to Entyvio®

Feb 5, 2026, 3:00 AM EST - 2 months ago

Alvotech Announces Positive Top-Line Results from Pivotal Pharmacokinetic Study for Proposed Biosimilar to Entyvio®

Alvotech enters supply and commercialization agreements for Canada and Australia & New Zealand covering multiple biosimilar candidates

Feb 2, 2026, 3:00 AM EST - 2 months ago

Alvotech enters supply and commercialization agreements for Canada and Australia & New Zealand covering multiple biosimilar candidates

Alvotech: Why FDA Delays Don't Break The Bull Case

Jan 21, 2026, 9:34 PM EST - 2 months ago

Alvotech: Why FDA Delays Don't Break The Bull Case

Bragar Eagel & Squire, P.C. Continues Investigations into Alvotech and Beyond Meat on Behalf of Stockholders and Encourages Investors to Contact the Firm

Jan 13, 2026, 3:22 PM EST - 2 months ago

Bragar Eagel & Squire, P.C. Continues Investigations into Alvotech and Beyond Meat on Behalf of Stockholders and Encourages Investors to Contact the Firm

BYND

Correction: Transactions of Managers and Closely Associated Persons

Jan 7, 2026, 5:00 PM EST - 3 months ago

Correction: Transactions of Managers and Closely Associated Persons

Transactions of Managers and Closely Associated Persons

Jan 6, 2026, 3:00 PM EST - 3 months ago

Transactions of Managers and Closely Associated Persons

Alvotech Secures Term Loan Facility of USD 100 Million

Dec 31, 2025, 4:30 PM EST - 3 months ago

Alvotech Secures Term Loan Facility of USD 100 Million

Changes in company's own shares

Dec 29, 2025, 2:40 PM EST - 3 months ago

Changes in company's own shares

Alvotech's Financial Calendar for 2026

Dec 22, 2025, 3:26 PM EST - 3 months ago

Alvotech's Financial Calendar for 2026

Alvotech announces European launch of first-in-market biosimilar to Simponi® (golimumab) globally by partner Advanz Pharma

Dec 22, 2025, 2:00 AM EST - 3 months ago

Alvotech announces European launch of first-in-market biosimilar to Simponi® (golimumab) globally by partner Advanz Pharma

Alvotech (ALVO) Faces Investor Scrutiny Amid Manufacturing Deficiencies Severely Impacting Assurances of 2025 Revenues and Adjusted EBITDA, Stock Tumbles 33% -- Hagens Berman

Dec 17, 2025, 4:08 PM EST - 3 months ago

Alvotech (ALVO) Faces Investor Scrutiny Amid Manufacturing Deficiencies Severely Impacting Assurances of 2025 Revenues and Adjusted EBITDA, Stock Tumbles 33% -- Hagens Berman

Alvotech Successfully Places USD 108 Million Senior Unsecured Convertible Bonds in a Significantly Oversubscribed Offering

Dec 17, 2025, 2:30 AM EST - 3 months ago

Alvotech Successfully Places USD 108 Million Senior Unsecured Convertible Bonds in a Significantly Oversubscribed Offering

Alvotech (ALVO) Discusses Launch of $125 Million Commercial Bond Offering and Business Update Transcript

Dec 16, 2025, 3:19 PM EST - 3 months ago

Alvotech (ALVO) Discusses Launch of $125 Million Commercial Bond Offering and Business Update Transcript

Alvotech Announces Approval of AVT03, a Biosimilar to Prolia® and Xgeva® (denosumab) in the European Economic Area

Nov 24, 2025, 5:30 AM EST - 4 months ago

Alvotech Announces Approval of AVT03, a Biosimilar to Prolia® and Xgeva® (denosumab) in the European Economic Area

Alvotech and Advanz Pharma Receive Marketing Approval Across the European Economic Area for Gobivaz®, a First-in-Market Biosimilar to Simponi® (golimumab)

Nov 20, 2025, 4:00 AM EST - 4 months ago

Alvotech and Advanz Pharma Receive Marketing Approval Across the European Economic Area for Gobivaz®, a First-in-Market Biosimilar to Simponi® (golimumab)

Alvotech (ALVO) Q3 2025 Earnings Call Transcript

Nov 13, 2025, 10:51 AM EST - 5 months ago

Alvotech (ALVO) Q3 2025 Earnings Call Transcript

Alvotech Reports Results for the First Nine Months of 2025 and Provides a Business Update

Nov 12, 2025, 4:40 PM EST - 5 months ago

Alvotech Reports Results for the First Nine Months of 2025 and Provides a Business Update

Scott+Scott Attorneys at Law LLP Reminds Investors of Its Investigation into Alvotech (NASDAQ: ALVO)

Nov 10, 2025, 5:28 PM EST - 5 months ago

Scott+Scott Attorneys at Law LLP Reminds Investors of Its Investigation into Alvotech (NASDAQ: ALVO)

Scott+Scott Attorneys at Law LLP Alerts Investors of Its Investigation into Alvotech (NASDAQ: ALVO)

Nov 6, 2025, 6:28 PM EST - 5 months ago

Scott+Scott Attorneys at Law LLP Alerts Investors of Its Investigation into Alvotech (NASDAQ: ALVO)

Alvotech and Advanz Pharma Receive Marketing Authorisations for Gobivaz®, a Biosimilar to Simponi® (golimumab), from the MHRA

Nov 6, 2025, 9:07 AM EST - 5 months ago

Alvotech and Advanz Pharma Receive Marketing Authorisations for Gobivaz®, a Biosimilar to Simponi® (golimumab), from the MHRA

Alvotech Announces Webcast on November 13, 2025 to Report Financial Results for the First Nine Months of 2025 and Provide a Business Update

Nov 4, 2025, 4:01 PM EST - 5 months ago

Alvotech Announces Webcast on November 13, 2025 to Report Financial Results for the First Nine Months of 2025 and Provide a Business Update

Alvotech Shares Plunge 33% After FDA Flags Issues

Nov 3, 2025, 1:17 PM EST - 5 months ago

Alvotech Shares Plunge 33% After FDA Flags Issues

Alvotech Provides Update on the Status of U.S. Biologics License Application for AVT05

Nov 2, 2025, 5:12 PM EST - 5 months ago

Alvotech Provides Update on the Status of U.S. Biologics License Application for AVT05

Alvotech Announces Changes in Global Business Development and Commercial Operations Team

Oct 22, 2025, 5:00 AM EDT - 5 months ago

Alvotech Announces Changes in Global Business Development and Commercial Operations Team

Alvotech: Promising Vertically Integrated Biosimilar Platform

Oct 15, 2025, 4:18 AM EDT - 6 months ago

Alvotech: Promising Vertically Integrated Biosimilar Platform

My Top 5 Biotech Stocks Big Pharma Could Buy Next

Oct 6, 2025, 1:29 PM EDT - 6 months ago

My Top 5 Biotech Stocks Big Pharma Could Buy Next

ABBV AMGN ARKG AZN BIIB BMY GILD

European Marketing Application for AVT23, a Proposed Biosimilar to Xolair® (omalizumab), Accepted by the European Medicines Agency

Oct 6, 2025, 4:40 AM EDT - 6 months ago

European Marketing Application for AVT23, a Proposed Biosimilar to Xolair® (omalizumab), Accepted by the European Medicines Agency

European Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech's Proposed Biosimilar to Prolia® and Xgeva®

Sep 22, 2025, 6:15 AM EDT - 6 months ago

European Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech's Proposed Biosimilar to Prolia® and Xgeva®

European Medicines Agency Recommends Marketing Approval of Gobivaz®, Alvotech's Proposed Biosimilar to Simponi® (golimumab) with Advanz Pharma as Commercialization Partner

Sep 22, 2025, 4:30 AM EDT - 6 months ago

European Medicines Agency Recommends Marketing Approval of Gobivaz®, Alvotech's Proposed Biosimilar to Simponi® (golimumab) with Advanz Pharma as Commercialization Partner

Alvotech Announces Marketing Approval in Japan of Three New Biosimilars

Sep 19, 2025, 7:45 AM EDT - 7 months ago

Alvotech Announces Marketing Approval in Japan of Three New Biosimilars

Alvotech (ALVO) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 10, 2025, 1:28 PM EDT - 7 months ago

Alvotech (ALVO) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Alvotech Meets Investors and Participates in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York

Sep 4, 2025, 9:15 AM EDT - 7 months ago

Alvotech Meets Investors and Participates in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York

Advanz Pharma and Alvotech receive European approval for Mynzepli®, Biosimilar to Eylea®

Aug 21, 2025, 4:30 AM EDT - 8 months ago

Advanz Pharma and Alvotech receive European approval for Mynzepli®, Biosimilar to Eylea®

Alvotech appoints Patrik Ling as VP of Investor Relations Scandinavia

Aug 20, 2025, 6:05 AM EDT - 8 months ago

Alvotech appoints Patrik Ling as VP of Investor Relations Scandinavia

Alvotech (ALVO) Q2 2025 Earnings Call Transcript

Aug 14, 2025, 11:38 AM EDT - 8 months ago

Alvotech (ALVO) Q2 2025 Earnings Call Transcript

Alvotech Reports Results for the First Six Months of 2025 and Provides a Business Update

Aug 13, 2025, 4:15 PM EDT - 8 months ago

Alvotech Reports Results for the First Six Months of 2025 and Provides a Business Update

Alvotech Reports Results for the First Six Months of 2025 and Provides a Business Update

Aug 13, 2025, 4:15 PM EDT - 8 months ago

Alvotech Reports Results for the First Six Months of 2025 and Provides a Business Update

JohnTill
JohnTill Apr. 4 at 6:49 PM
$ALVO 4.10-4.25 coming within the next 5-7 trading session? Way too obvious? So many things lining up on the chart saying this is the next move (falling wedge, 50MA, etc, etc.). The fundamentals scream double digits within the next 18 months with FDA, US partner and new drug news coming soon so I should not even care but happy with some small baby steps. Now I am pissed I did not more than double up below 3.25 when given the chance but at least now well into the money on the trade. See where the week takes us.
0 · Reply
JohnTill
JohnTill Apr. 1 at 2:39 PM
$ALVO This would be a VERY good time for the company to put out FDA news or annouce a new US partner agreement. Finally some momentum in the right direction at that 50MA at 4.27 is just itching to get tested on news. After that - the GAP! At least I am well into the profit side again with more then tripling my position below 3.25 that in late March. I was definitely not loving buying into the that hole and on to brighter days.
0 · Reply
JohnTill
JohnTill Mar. 31 at 2:38 AM
$ALVO ALVO 20-F released and explains the strength today. I checked the SEC account mid-day and saw nothing but up there now. Well written all public items and could not find anything of major note. The major item is the next 9 months hinges on FDA approval. Approval by October and they will hit the high end of projections and more than enough cash flow for full speed expansion and debt knock-down. I see no reason why they will not get FDA approval and the only question is Sept. or Dec. and two years from now makes little difference. I do like that along with 30+ biosimilars in the pipeline they also talk about acquiring or in-license additional products and expansion into more expensive clinical programs. There are so many bullets in this gun and each one is a billion+ dollar target.
0 · Reply
JohnTill
JohnTill Mar. 30 at 7:49 PM
$ALVO Weird strength in a weak market on no news. Did someone let the cat out of the bag that the FDA filing is coming very soon or the new US partner agreement? Maybe UBS analyst Ashwani Verma buy rating from last week is finally making the rounds. Only a 6.00 price target but that is because everyone is holding out for FDA approval, new US partner and US drug launch. Once those hit we fill the gap and double digits and a rollercoaster until then.
0 · Reply
JohnTill
JohnTill Mar. 26 at 3:57 PM
$ALVO We could use some good news. I just noticed in the conference call notes “So that is why we're in the final stretches of being ready to submit. We're working really hard to do it by the end of the first quarter.”….. FDA news in the next few days? All changes done and running since late 2025. Filing starts the 6 month timer and inventory ready to flood the US potentially as soon as Oct. Also, could get the US partner news anytime and several pipeline updates. Upped my position by 40% this past few days between 3.22 and 3.05. Sitting with mid-3 avg. now and second largest position. Let the sweating starts. Delays get us into the twos and will add more since there is no way this is not healthy double digits by 2028 or sooner.
0 · Reply
Spytime
Spytime Mar. 26 at 1:20 PM
$ALVO waiting to open buy position soon. Waiting for panic retail to sell.
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 24 at 11:42 PM
$ALVO RSI: 31.19, MACD: -0.3075 Vol: 0.28, MA20: 3.77, MA50: 4.47 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
erevnon
erevnon Mar. 24 at 2:44 PM
Barclays maintains Alvotech $ALVO at Underweight and lowers the price target from $5 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
Explorer2234
Explorer2234 Mar. 24 at 2:35 PM
$ALVO lol wtf is going on with the price? Massive upside potential?
0 · Reply
diggs24
diggs24 Mar. 24 at 2:22 PM
$ALVO added 580@$3.07
0 · Reply
Toffik72
Toffik72 Mar. 24 at 9:13 AM
$ALVO UBS analyst Ashwani Verma reiterated a Buy rating on Alvotech today and set a price target of $6.00. https://www.tipranks.com/news/ratings/alvotech-regulatory-setbacks-priced-in-biosimilar-strength-supports-buy-rating-despite-lowered-target-ratings-news?utm_source=marketchameleon.com&utm_medium=referral
0 · Reply
diggs24
diggs24 Mar. 23 at 5:15 PM
$ALVO Added 550@$3.35
0 · Reply
Kosmokrat
Kosmokrat Mar. 23 at 3:40 PM
$ALVO just completed another round of financing in December, which should be sufficient until they are cash-flow positive. Which they should be this year. Remember, their sales are ramping up, while the new FDA guidance to no longer requires phase 3 studies for biosimilars, which reduces cost significantly for them.
0 · Reply
Windy007
Windy007 Mar. 20 at 1:46 PM
$ALVO DNB Carnegie lowers target price for Alvotech to SEK 50 (70), reiterates buy. That translates to $5.36 USD
0 · Reply
diggs24
diggs24 Mar. 20 at 12:59 PM
$ALVO That's just an opportunity to add more shares.
0 · Reply
Brunon77
Brunon77 Mar. 20 at 7:41 AM
$ALVO don't you see the risk of new share issuances for financing new pipelines
1 · Reply
diggs24
diggs24 Mar. 19 at 8:16 PM
$ALVO Same. Added 375@$3.58 and 400@$3.45
0 · Reply
JohnTill
JohnTill Mar. 19 at 7:51 PM
$ALVO Added to the growing pile today in the $3.45-$3.55 range following the earnings call. The biggest catalyst by far: Management annoucing the U.S.-based CMO partner with costs fitting right inside their anticipated R&D and CapEx budgets and happening next quarter. This kills the Single-Site Risk - moves them away from total dependency on the Iceland. The U.S. is 60%+ of the biologics market. US production aligns with long-term government trends prioritizing homegrown supply chains (tariffs are small). Also provides scaling for multiple upcoming launches and will also gives U.S. commercial partners much more confidence in the supply chain. Only downside I see is some slight margin pressure on the CMO side and a bit more regulatory legwork for the tech transfers. This pivot is a major de-risking event and I see US big money flowing much easier into this story down the road with a domestic manufacturing solution is in place. Maybe that gap gets filled sooner than I thought.
1 · Reply
StocktwitsEarnings
StocktwitsEarnings Mar. 19 at 10:00 AM
$ALVO Q4 '25 Earnings Results & Recap Alvotech reaffirms 2026 outlook, projecting total revenues of $650M and Adjusted EBITDA increasing to $180M. U.S. approval for four BLAs is anticipated by late 2026, with minimal topline impact for the year.
0 · Reply
JohnTill
JohnTill Mar. 18 at 10:38 PM
$ALVO Adjusted EBITDA $69M in Q4, gross margins of 66% - getting some decent real operational leverage. 2026 guidance of $650M–$700M in revenue and $180M–$220M in Adjusted EBITDA and this is without the US launch. Submitting FDA docs in Q2 and hopefully early in Q2 to get us an early Q4 approval. The main two quotes " global partners which provide Alvotech with commercial reach into 90 countries worldwide" and "leading pipeline of 30 biosimilars in development and continue adding to it at an accelerated pace.". Think it will take the FDA approval to fill that gap to $8 and I have the time and will add on weakness. A few year from now people will be wondering how this ever trade in the 3s.
0 · Reply
deedeethegenius
deedeethegenius Mar. 18 at 5:48 PM
$ALVO
0 · Reply